This application is a continuation-in-part of U.S. patent application Ser. No. 14/265,228 filed Apr. 29, 2014 and entitled “Systems and Methods for the Treatment of Eye Conditions”, which claims the benefit of U.S. Provisional Application No. 61/817,757, filed Apr. 30, 2013, which are incorporated herein by reference, and related to U.S. patent application Ser. No. 14/529,102 and entitled “Systems and Methods for the Treatment of Eye Conditions”, which is also incorporated herein by reference.
The present disclosure relates to medical devices and methods of using the same. More particularly, the disclosure relates to systems, methods, and apparatus used to treat eyelashes and surrounding tissue.
Eyelashes grow at the edge of the eyelid and help filter out foreign matter, including dust and debris, and prevent the foreign matter from getting into the eye. An eyelash is sensitive to being touched, thus providing a warning that an object may be too close to the eye. Many people lose their eyelashes, a condition called madarosis. There are numerous conditions that can result in eyelash loss, including ophthalmological conditions, such as blepharitis, dermatologic conditions, Nutritional defects, Infections, Trauma, Drugs/Medications, Genetics, and other diseases.
A blepharitis attack of eyelids repeatedly can cause eyelash loss. It causes swelling and itching on the eyelid due to excessive bacteria growth in tiny oil glands. Antibiotics are typically used to combat the bacterial infection. Blepharitis can include anterior blepharitis or posterior blepharitis. Anterior blepharitis is usually either staphylococcal or seborrhoeic, and posterior blepharitis refers to any of the varieties of meibomian gland dysfunction. The symptoms of anterior blepharitis include itching, burning, foreign body sensation, photophobia, and tearing. Posterior blepharitis is also known as meibomian gland dysfunction and is characterized by either excessive foam in the tear film in the hypersecretory type, or plugging of the meibomian orifices in the obstructive type. Expression of the secretions reveals a turbid or toothpaste-like material. If there is spillover inflammation of the anterior lid margin, there may be a loss of eyelashes.
A need exists for improved methods and devices to diagnose and treat eyelash loss.
Embodiments described herein may meet one or more of the needs identified above and may overcome one or more of the shortcomings of current eyelash treatment methods. Various implementations of systems, methods, and devices within the scope of the appended claims each have several aspects, no single one of which is solely responsible for the desirable attributes described herein. Without limiting the scope of the appended claims, some prominent features are described herein.
The present application relates generally to treatment systems, methods, and devices used to treat eyelids, in particular, the eyelid margin where the eyelashes grow. Details of one or more implementations of the subject matter described in this specification are set forth in the accompanying drawings and the description below. Other features, embodiments, and advantages will become apparent from the description, the drawings, and the claims.
One aspect of this disclosure provides a device for stimulating and/or promoting eyelash growth. In various embodiments, the device includes an energy transducer configured to provide light energy at one or more wavelengths and a scleral shield. When the eyelid is positioned between the energy transducer and the scleral shield, the light energy from the energy transducer is directed to the eyelid margin to provide light energy at an output wavelength suitable for stimulating and/or promote eyelash hair growth.
An additional aspect of the disclosure provides a method for promoting eyelash growth. The method includes positioning an energy transducer proximate an eyelash region of the eyelid, the energy transducer configured to provide light energy at one or more wavelengths, and positioning a scleral shield between the energy transducer and eyeball, the scleral shield being made of, or coated with, a light energy blocking material. The method also includes directing light energy from the energy transducer toward the eyelash region at a first wavelength suitable for stimulating and/or promoting eyelash hair growth; and blocking any light energy directed toward the eyeball with the scleral shield to protect the eyeball from the light energy.
In some embodiments, the energy transducer is further configured to provide light energy at a second wavelength selected to treat bacteria. In some embodiments, the energy transducer is further configured to provide light energy at a third wavelength selected to be absorbed by the eyelid tissue, and thereby heat the eyelid tissue. The first wavelength may be in the range of about (without limitation) 450-700 nm, the second wavelength may be in the range of about (without limitation) 400-450 nm and the third wavelength may be in the range of about (without limitation) 700-1000 nm.
In some embodiments, the energy transducer may include at least one of an LED, laser, incandescent lamp, xenon lamp, halogen lamp, luminescent lamp, high-intensity discharge lamp, and gas discharge lamp.
Some embodiments of the device further include one or more components selected from the group consisting of: a display or dashboard configured to display the device status; a battery configured to power the device components; battery charging means; a controller; printed circuit board; and communication circuitry between scleral shield and energy transducer.
Some embodiments of the device further include a safety feature electrically coupled to the energy transducer configured to prevent or interrupt the light energy from the energy transducer if the if the scleral shield and associated assembly are not properly attached to, and aligned with, the device.
Additionally, or alternatively, some embodiments of the device further include a timer operatively coupled to the energy transducer and configured to shut off the energy transducer after a predetermined time.
Other features and advantages should be apparent from the following description of various implementations, which illustrate, by way of example, the principles of the invention.
The above-mentioned aspects, as well as other features, aspects, and advantages of the present technology will now be described in connection with various embodiments, with reference to the accompanying drawings. The illustrated embodiments, however, are merely examples and are not intended to be limiting. Throughout the drawings, similar symbols typically identify similar components, unless context dictates otherwise. Note that the relative dimensions of the following figures may not be drawn to scale.
In the following detailed description, reference is made to the accompanying drawings, which form a part of the present disclosure. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, and designed in a wide variety of different configurations, all of which are explicitly contemplated and form part of this disclosure.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. It will be understood by those within the art that if a specific number of a claim element is intended, such intent will be explicitly recited in the claim, and in the absence of such recitation, no such intent is present. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. It will be further understood that the terms “comprises,” “comprising,” “have,” “having,” “includes,” and “including,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.
To assist in the description of the devices and methods described herein, some relational and directional terms are used. “Connected” and “coupled,” and variations thereof, as used herein include direct connections, such as being contiguously formed with, or glued, or otherwise attached directly to, on, within, etc. another element, as well as indirect connections where one or more elements are disposed between the connected elements. “Connected” and “coupled” may refer to a permanent or non-permanent (i.e., removable) connection.
“Secured” and variations thereof as used herein include methods by which an element is directly secured to another element, such as being glued, screwed, or otherwise fastened directly to, on, within, etc. another element, as well as indirect means of securing two elements together where one or more elements are disposed between the secured elements.
“Proximal” and “distal” are relational terms used herein to describe position from the perspective of a medical professional treating a patient. For example, as compared to “distal,” the term “proximal” refers to a position that is located more closely to the medical professional, while the distal end is located more closely to the patient during treatment. For example, the distal ends of the devices disclosed herein oppose the proximal ends of the same devices, and the distal end of a device often includes, for example, the end configured for placement against the eyelid of a patient.
“Transducer” is a term used herein to describe an element which receives one form of energy and transforms it into another. For example, a light source may receive electrical energy and produce light energy. Likewise, an ultrasonic transducer may receive electrical energy and produce ultrasonic energy.
“Light” as used herein refers not only to energy in the visible light spectrum, but also to energy in the infrared and ultraviolet portions of the electromagnetic energy spectrum.
“Waveguide” as used herein refers to any means of influencing the propagation, distribution or trajectory of electromagnetic energy such as light, ultrasonic energy and radio frequency energy. As defined herein, optical elements such as diffractors, refractors, diffusers and the like are included in this broad definition of a waveguide.
“Optical path length” is used herein to describe the length of the path (for example, within a tissue section) through which energy travels.
Embodiments disclosed herein relate to ophthalmic devices, systems, and methods. The devices, systems, and methods disclosed herein can be used to for stimulating and/or promoting eyelash growth.
The power source module 110 of various embodiments provides energy to the energy transducer module 120. The power source module 110 may include any structure configured for delivering power to one or more other components of the eyelash treatment device 100. In some embodiments, the power source module 110 includes a disposable battery, a rechargeable battery, a solar cell, a power transforming module such as a power supply or power converter, or a power transfer mechanism such as a cord, outlet, or plug configured to receive alternating current or direct current from an external source.
The energy transducer module 120 may include one or more energy transducers configured to emit one or more forms or type of energy. For example, as described in more detail below, in some embodiments, the energy transducers emit photonic, acoustic, radio frequency, electrical, magnetic, electro-magnetic, vibrational, infrared or ultrasonic energy. In some embodiments, the transducer module 120 generates multiple types of energy simultaneously or in a predetermined order.
In some embodiments, the transducer module 120 may generate multiple types of energy simultaneously, such as photonic, acoustic, radio frequency, electrical, magnetic, electro-magnetic, vibrational, infrared or ultrasonic energy. For example, a first energy may treat the eyelash at the eyelid margin while a second energy may treat for bacteria on the eyelid.
The embodiment shown in
The eyelash treatment device 200 of
In certain embodiments having a controller 212, the controller 212 can receive input instructions from a user (for example, through a user interface device, such as a button, switch, touch screen, voice commands, from another module or device, such as a smartphone) to emit light from the energy transducer module 120. Upon receipt of the user input instructions, the controller 212 can instruct the power source module 110 to deliver energy to or from the energy transducer module 120.
The energy transducer module 120 can be configured to emit light of the appropriate wavelength necessary for the desired treatment. The treatments may include one or more of the following: promoting eyelash growth by the illuminating the eyelid margins, antibacterial treatment to kill bacteria in the eye system 10, and heating the meibomian gland of eyelids 12, 14. Note that the descriptions of the various devices herein (including the eyelash treatment device 200) are exemplary, and not limiting. Thus, for example, while this detailed description mentions particular elements and circuitry having particular functions, this does not limit the disclosure to those particular embodiments. For example, while LEDs are mentioned, other light sources, such as incandescent, xenon, halogen, high-intensity discharge, cold cathode tube, fluorescent, laser and other light sources or energy sources can be used.
For some embodiments, it is desirable to use light with a wavelength selected to: a) stimulate and/or promote eyelash growth at the eyelash region of an eyelid, b) reduce or minimize the amount of light that penetrates beyond the eyelash region, and c) reduce or minimize the amount of heating that occurs at the surface of the eyelid. For example, in some embodiments, the energy transducer 120 can emit light having a wavelength in the range of about 450-700 nm. Furthermore, emitting wavelengths within this portion of the light spectrum avoids the undesired portion of the electromagnetic spectrum for embodiments that do not incorporate a scleral shield, including ultraviolet, infrared, and blue.
In some embodiments, the energy transducer is further configured to provide light energy at a second wavelength selected to treat bacteria. In some embodiments, the energy transducer is further configured to provide light energy at a third wavelength selected to be absorbed by the eyelid tissue, and thereby heat the eyelid tissue. The first wavelength may be in the range of about (without limitation) 450-700 nm, the second wavelength may be in the range of about 400-450 nm and the third wavelength may be in the range of about 700-1000 nm.
While a controller 212 and energy transducer 120 are mentioned, it will be understood that the controller could be integrated with driver circuitry for the light source or circuitry for a solid-state or other power supply, or other configurations could be used to provide the desired result. Further, some or all of the functions described as being handled by, or controlled by, controller 212, may be implemented using discrete logic or analog circuitry, or a combination thereof.
Moreover, although the various embodiments such as device 200 are illustrated schematically, they can be produced in a variety of handheld or stationary configurations with a housing with optional gripping surfaces, manipulation and control structures, and the like.
In one embodiment, a handheld light therapy device 200 includes a housing 202, an energy transducer module 120 positioned at a distal end of the housing, a power source module coupled to the energy transducer module, a controller 212 coupled to the power source module, and a user interface controller coupled to the controller configured to provide user input to the controller to instruct the power source module to deliver energy to or from the energy transducer module. Examples of a user interface include a button, switch, touch screen or voice commands. The user interface may be incorporated into the device, it may be located on another module or device in communication with the handheld light therapy device 200, such as a smartphone that wirelessly communicates with the controller.
The handheld light therapy device 200 further includes a scleral shield 300 configured to block light energy toward the eyeball, the scleral shield being positioned between the energy transducer and the eyeball. In use, the eyelash region is positioned in a gap between the energy transducer and the scleral shield and the energy transducer is instructed to provide light energy 211 at a first wavelength to the eyelash region, and the scleral shield blocks and/or protects the eyeball from the light energy.
It is desirable to use light with a wavelength selected to stimulate and/or promote eyelash growth at the eyelash region of an eyelid. For example, in some embodiments, the energy transducer 120 can emit light having a wavelength in the range of about 450-700 nm. In some embodiments, the energy transducer is further configured to provide light energy at a second wavelength selected to treat bacteria, for example in the range of about 400-450 nm. In some embodiments, the energy transducer is further configured to provide light energy at a third wavelength selected to be absorbed by the eyelid tissue, and thereby heat the eyelid tissue, for example, in the range of about 700-1000 nm.
In some embodiments, the handheld light therapy device 200 may include a display or dashboard configured to display the device status. The display or dashboard may be on the device, such as on the housing, or the display or dashboard may be on a separate device, such as another module or device, or a smartphone in wireless communication. The handheld light therapy device 200 may also use a power cord or a battery configured to power the device components and battery charging means.
The handheld light therapy device 200 may also include a safety feature electrically coupled to the energy transducer prevents or interrupts the light energy from occurring if the scleral shield is not in position to protect the eyeball. In some embodiments, the safety feature may include sensors to make sure that a protective scleral shield 300 is in the correct position prior to turning on an energy transducer module 120, thus preventing damage to the eye system 10, sensors for preventing undesired activation of the device, sensors monitoring the delivery of energy to the patient, or sensors for preventing overheating of the skin. In some embodiments, the safety feature may include safety warning apparatus to let the patient know of an unsafe condition, and can include a flashing light, a flashing warning, a sound warning beep, a picture, a vibration pattern, or words indicative of the potential for or existence of an unsafe condition.
The devices described herein can be designed for use in a plurality of settings, including in-home use and use within an eye care professional's office, a health clinic, or other healthcare facility.
The eyelash treatment device 200 of various embodiments may also include one or more thermal management structures configured to cool at least a portion of the device. In some embodiments, the thermal management structures are provided to manage the heat of the energy transducer module 120 and prevent the device 200 from overheating. Additionally, or alternatively, in some embodiments, the thermal management structures are provided to cool a surface of the eyelid to limit discomfort and avoid injury to the eyelid tissue during treatment. In
The embodiment of
The energy transducer module 120 can include a lens 208 that can be used in conjunction with the LED emitter 207 or other electromagnetic energy source to direct the energy to the eyelid at a desired angle or in a desired pattern, at a desired intensity.
The energy transmission surface 140 may be configured to direct energy generated by the energy transducer module 120 toward a desired region. The energy transmission surface 140 may include one or more lenses configured to focus energy generated by the transducer module 120. The energy transmission surface 140 may contact the surface of the eyelid 12, 14. In some embodiments, at least a portion of energy transmission surface 140 may be configured as a single-use cover element.
As depicted in
Referring back to
It will be further appreciated that the scleral shield 300 may include features which provide even more benefits to the device. For example, the scleral shield 300 of some embodiments is configured to reflect energy away from the eyeball and toward the inner eyelids, providing heating to the inner eyelids. In some embodiments, the scleral shield 300 may be made of, or coated with, a light energy blocking material.
In some embodiments, an illumination source emitting blue or violet light in the range of 400-450 nm may be used to reduce and/or eliminate bacteria in the eye system 10. It is known that exposure to visible light, more specifically, blue or violet light wavelengths, causes inactivation of certain bacterial species. Common bacteria include S. aureus, S. epidermidis, B. oleronius, and P. acnes. In selecting wavelengths in the range of 400-450 nm, a plurality of considerations may be taken into account. For example, it is important that the emitting source (LED) does not emit a significant amount of energy below about 400 nm, which is in the UVA spectrum and can be associated with skin cancer.
In another embodiment utilizing LEDs as an illumination source, the LED emitter 207 can include one or more multi-spectral LEDs or multiple LEDs to emit light of differing or the same wavelength from each LED. In some embodiments, each LED of the LED emitter 207 is configured to emit light of a different wavelength. The LED emitter 207 can emit the light from each differently colored LED either consecutively or simultaneously. For example, in some embodiments, the LED emitter 207 can include a red, green, blue (RGB) LED system, or other multi-spectral LED system, to emit light of various wavelengths in the visible light spectrum and IR spectrum. In some embodiments, the LEDs of the LED emitter 207 can be configured to operate simultaneously to emit white light. Alternatively, in some embodiments, the user can select the wavelength of light to be emitted from the multi-spectral LEDs. Further, an LED with using a special phosphorescent coating may be fabricated in order to produce the most efficient output spectrum relative to input power.
In some embodiments, the energy transducer may also provide light energy at a second wavelength selected to treat bacteria, for example, a suitable wavelength may be in the range of 400-450 nm. In still other embodiments, the energy transducer may also provide light energy at a third wavelength to soften or melt meibum within meibomian glands, for example, a suitable wavelength may be in the range of about 700-1000 nm. These wavelengths are only examples and the invention is not limited to these ranges.
Patient safety and comfort are important considerations in the present device and method. Safety sensors and warnings can thus advantageously be incorporated into the device. These include sensors to make sure that a protective scleral shield 300 is in the correct position prior to turning on an energy transducer module 120, thus preventing damage to the eye system 10, sensors for preventing undesired activation of the device, sensors monitoring the delivery of energy to the patient, or sensors for preventing overheating of the skin. A safety warning apparatus can be incorporated into the device to let the patient know of an unsafe condition, and can include a flashing light, a flashing warning, a sound warning beep, a picture, a vibration pattern, or words indicative of the potential for or existence of an unsafe condition.
For purposes of summarizing the disclosure, certain aspects, advantages and features have been described herein. It is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
While this disclosure has been described in connection with what are presently considered to be practical embodiments, it will be appreciated by those skilled in the art that various modifications and changes may be made without departing from the scope of the present disclosure. It will also be appreciated by those of skill in the art that parts mixed with one embodiment are interchangeable with other embodiments; one or more parts from a depicted embodiment can be included with other depicted embodiments in any combination. For example, any of the various components described herein and/or depicted in the Figures may be combined, interchanged or excluded from other embodiments. With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity.
While the present disclosure has described certain exemplary embodiments, it is to be understood that the disclosure is not limited to the disclosed embodiments, but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the scope of the appended claims, and equivalents thereof.
Number | Name | Date | Kind |
---|---|---|---|
793004 | May | Jun 1905 | A |
1006945 | Houston | Oct 1911 | A |
1714693 | Renwick | May 1929 | A |
1924315 | Hemphill et al. | Aug 1933 | A |
1963990 | Gilkeson et al. | Jun 1934 | A |
2183726 | Sommer et al. | Dec 1939 | A |
2204631 | Tillyer | Jun 1940 | A |
2231112 | Conner | Feb 1941 | A |
2407518 | Schauweker | Sep 1946 | A |
2545724 | Curtis | Mar 1951 | A |
2555636 | Felts et al. | Jun 1951 | A |
2690173 | Seeger et al. | Sep 1954 | A |
2891252 | Lazo | Jun 1959 | A |
3140390 | Smith et al. | Jul 1964 | A |
3173419 | Dubilier et al. | Mar 1965 | A |
3333586 | Bellis et al. | Aug 1967 | A |
3404678 | Von Ardenne | Oct 1968 | A |
3411364 | Horley et al. | Nov 1968 | A |
3485244 | Rosen | Dec 1969 | A |
3667476 | Muller | Jun 1972 | A |
3934585 | Maurice | Jan 1976 | A |
3952735 | Wirtschafter et al. | Apr 1976 | A |
RE28873 | Morgan | Jun 1976 | E |
4167942 | Brunelli | Sep 1979 | A |
4261364 | Haddad et al. | Apr 1981 | A |
4303063 | Stahl | Dec 1981 | A |
4387707 | Polikoff | Jun 1983 | A |
4398811 | Nishioka et al. | Aug 1983 | A |
4549051 | Ness | Oct 1985 | A |
4554911 | Nielsen | Nov 1985 | A |
4570626 | Norris et al. | Feb 1986 | A |
4669834 | Richter | Jun 1987 | A |
4736743 | Daikuzono | Apr 1988 | A |
4778457 | York | Oct 1988 | A |
4784165 | Stein | Nov 1988 | A |
4824730 | Fukuda et al. | Apr 1989 | A |
4883454 | Hamburg | Nov 1989 | A |
4914088 | Glonek et al. | Apr 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4958632 | Duggan | Sep 1990 | A |
5030214 | Spector | Jul 1991 | A |
5097829 | Quisenberry | Mar 1992 | A |
5151100 | Abele et al. | Sep 1992 | A |
5158082 | Jones | Oct 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
5213097 | Zeindler | May 1993 | A |
5224469 | Mocny | Jul 1993 | A |
5251025 | Cooper et al. | Oct 1993 | A |
5251627 | Morris | Oct 1993 | A |
5283063 | Freeman | Feb 1994 | A |
5314456 | Cohen | May 1994 | A |
5343561 | Adamo | Sep 1994 | A |
D352106 | Fanney et al. | Nov 1994 | S |
5368582 | Bertera | Nov 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5377701 | Fang | Jan 1995 | A |
5417686 | Peterson et al. | May 1995 | A |
5425380 | Hudson et al. | Jun 1995 | A |
5484432 | Sand | Jan 1996 | A |
5496311 | Abele et al. | Mar 1996 | A |
5601548 | Smith et al. | Feb 1997 | A |
5627611 | Scheiner | May 1997 | A |
5628772 | Russell | May 1997 | A |
5643336 | Lopez-Claros | Jul 1997 | A |
5690608 | Watanabe et al. | Nov 1997 | A |
5700238 | Hyson | Dec 1997 | A |
5720773 | Lopez-Claros | Feb 1998 | A |
5769806 | Radow | Jun 1998 | A |
5807357 | Kang | Sep 1998 | A |
5836927 | Fried | Nov 1998 | A |
5893719 | Radow | Apr 1999 | A |
5958912 | Sullivan | Sep 1999 | A |
5964723 | Augustine | Oct 1999 | A |
6024095 | Stanley, III | Feb 2000 | A |
6058324 | Chance | May 2000 | A |
6059772 | Hsia et al. | May 2000 | A |
6098628 | Funk | Aug 2000 | A |
6107289 | Sullivan | Aug 2000 | A |
6110292 | Jewett et al. | Aug 2000 | A |
6112900 | Adkins, Jr. | Sep 2000 | A |
6113561 | Augustine | Sep 2000 | A |
6123081 | Durette | Sep 2000 | A |
6153607 | Pflugfelder et al. | Nov 2000 | A |
6155995 | Lin | Dec 2000 | A |
6161546 | Yavitz | Dec 2000 | A |
6181970 | Kasevich | Jan 2001 | B1 |
6193740 | Rodriguez | Feb 2001 | B1 |
6201880 | Elbaum et al. | Mar 2001 | B1 |
6206842 | Tu et al. | Mar 2001 | B1 |
6213966 | Augustine | Apr 2001 | B1 |
6273886 | Edwards et al. | Aug 2001 | B1 |
6309364 | Cathaud et al. | Oct 2001 | B1 |
D456079 | Fujii | Apr 2002 | S |
6423018 | Augustine | Jul 2002 | B1 |
6425888 | Embleton et al. | Jul 2002 | B1 |
6438398 | Pflugfelder et al. | Aug 2002 | B1 |
6455583 | Pflugfelder et al. | Sep 2002 | B1 |
6482203 | Paddock et al. | Nov 2002 | B2 |
6490488 | Rudie et al. | Dec 2002 | B1 |
D472637 | Cooper et al. | Apr 2003 | S |
6544257 | Nagase et al. | Apr 2003 | B2 |
D477084 | Menezes et al. | Jul 2003 | S |
6641264 | Schwebel | Nov 2003 | B1 |
6648904 | Altshuler et al. | Nov 2003 | B2 |
6706001 | Fresco | Mar 2004 | B2 |
6743249 | Alden | Jun 2004 | B1 |
6780176 | Hasegawa | Aug 2004 | B2 |
6788977 | Fenn et al. | Sep 2004 | B2 |
6827898 | Fausset et al. | Dec 2004 | B1 |
6840954 | Dietz et al. | Jan 2005 | B2 |
6860852 | Schonenberger et al. | Mar 2005 | B2 |
6860880 | Treat et al. | Mar 2005 | B2 |
6874884 | Schwebel | Apr 2005 | B2 |
6882885 | Levy, Jr. et al. | Apr 2005 | B2 |
6886933 | Schwebel | May 2005 | B2 |
6897238 | Anderson | May 2005 | B2 |
6908195 | Fuller | Jun 2005 | B2 |
6925317 | Samuels et al. | Aug 2005 | B1 |
6974454 | Hooven | Dec 2005 | B2 |
6979328 | Baerveldt et al. | Dec 2005 | B2 |
6989007 | Shadduck | Jan 2006 | B2 |
7001379 | Behl et al. | Feb 2006 | B2 |
7004942 | Laird et al. | Feb 2006 | B2 |
7036928 | Schwebel | May 2006 | B2 |
7069084 | Yee | Jun 2006 | B2 |
7108694 | Miura et al. | Sep 2006 | B2 |
7118217 | Kardon et al. | Oct 2006 | B2 |
7118591 | Frank et al. | Oct 2006 | B2 |
7121666 | Tseng et al. | Oct 2006 | B2 |
7122013 | Liu | Oct 2006 | B2 |
7122047 | Grahn et al. | Oct 2006 | B2 |
7123968 | Casscells, III et al. | Oct 2006 | B1 |
7184827 | Edwards | Feb 2007 | B1 |
7211070 | Soroudi | May 2007 | B2 |
7229468 | Wong, Jr. et al. | Jun 2007 | B2 |
7231922 | Davison et al. | Jun 2007 | B2 |
D546459 | Banryu | Jul 2007 | S |
D552736 | Yamaoka | Oct 2007 | S |
D553750 | Yamaoka | Oct 2007 | S |
7316657 | Kleinhenz et al. | Jan 2008 | B2 |
7357500 | Schwebel | Apr 2008 | B2 |
7435252 | Krespi et al. | Oct 2008 | B2 |
7442174 | Butler | Oct 2008 | B2 |
7513893 | Soroudi | Apr 2009 | B2 |
7594728 | Seal et al. | Sep 2009 | B2 |
D612941 | Youngquist et al. | Mar 2010 | S |
D614774 | Gausmann et al. | Apr 2010 | S |
7712899 | Tanassi et al. | May 2010 | B2 |
7771342 | Rademacher et al. | Aug 2010 | B2 |
7811252 | Dacquay et al. | Oct 2010 | B2 |
7886748 | Boxer Wachler | Feb 2011 | B2 |
7976573 | Korb et al. | Jul 2011 | B2 |
7981146 | Korb et al. | Jul 2011 | B2 |
7981147 | Korb et al. | Jul 2011 | B2 |
8007424 | Moser et al. | Aug 2011 | B2 |
8025689 | Korb et al. | Sep 2011 | B2 |
8083787 | Korb et al. | Dec 2011 | B2 |
8187310 | Korb et al. | May 2012 | B2 |
8187311 | Korb et al. | May 2012 | B2 |
8202853 | Adkins, Jr. | Jun 2012 | B2 |
8235887 | Bayer et al. | Aug 2012 | B2 |
8249695 | Grenon et al. | Aug 2012 | B2 |
8255039 | Gravely et al. | Aug 2012 | B2 |
8348955 | Truckai et al. | Jan 2013 | B2 |
8409848 | Zeng et al. | Apr 2013 | B2 |
8491505 | Yang | Jul 2013 | B2 |
8491508 | Smith et al. | Jul 2013 | B2 |
8506539 | Guinan et al. | Aug 2013 | B2 |
8523928 | Korb et al. | Sep 2013 | B2 |
8562658 | Shoham | Oct 2013 | B2 |
8600484 | Grenon et al. | Dec 2013 | B2 |
8617229 | Korb et al. | Dec 2013 | B2 |
8628504 | Grenon et al. | Jan 2014 | B2 |
8632578 | Korb et al. | Jan 2014 | B2 |
8685073 | Korb et al. | Apr 2014 | B2 |
9060843 | Grenon et al. | Jun 2015 | B2 |
20010039442 | Gorge et al. | Nov 2001 | A1 |
20010041886 | Durkin et al. | Nov 2001 | A1 |
20020035345 | Beck | Mar 2002 | A1 |
20020099094 | Anderson | Jul 2002 | A1 |
20020111608 | Baerveldt et al. | Aug 2002 | A1 |
20020128696 | Pearl et al. | Sep 2002 | A1 |
20020180929 | Tseng et al. | Dec 2002 | A1 |
20030056281 | Hasegawa | Mar 2003 | A1 |
20030065277 | Covington | Apr 2003 | A1 |
20030069489 | Abreu | Apr 2003 | A1 |
20030100936 | Altshuler et al. | May 2003 | A1 |
20030114426 | Pflugfelder et al. | Jun 2003 | A1 |
20030139790 | Ingle et al. | Jul 2003 | A1 |
20030195438 | Petillo | Oct 2003 | A1 |
20030211043 | Korb | Nov 2003 | A1 |
20030233135 | Yee | Dec 2003 | A1 |
20040064169 | Briscoe et al. | Apr 2004 | A1 |
20040064171 | Briscoe et al. | Apr 2004 | A1 |
20040076695 | Gilbard | Apr 2004 | A1 |
20040111138 | Bleam et al. | Jun 2004 | A1 |
20040153093 | Donovan | Aug 2004 | A1 |
20040167499 | Grove et al. | Aug 2004 | A1 |
20040186534 | Shadduck | Sep 2004 | A1 |
20040199158 | Hood et al. | Oct 2004 | A1 |
20040237969 | Fuller | Dec 2004 | A1 |
20040249427 | Nabilsi | Dec 2004 | A1 |
20040260209 | Ella et al. | Dec 2004 | A1 |
20050022823 | Davison et al. | Feb 2005 | A1 |
20050119629 | Soroudi | Jun 2005 | A1 |
20050143798 | Bleam et al. | Jun 2005 | A1 |
20050177093 | Barry et al. | Aug 2005 | A1 |
20050220742 | Breen | Oct 2005 | A1 |
20050234506 | Weser | Oct 2005 | A1 |
20060018953 | Guillon et al. | Jan 2006 | A1 |
20060030604 | Elsinger et al. | Feb 2006 | A1 |
20060030908 | Powell et al. | Feb 2006 | A1 |
20060055878 | Yee | Mar 2006 | A1 |
20060069420 | Rademacher et al. | Mar 2006 | A1 |
20060104914 | Soroudi | May 2006 | A1 |
20060135890 | Tsai | Jun 2006 | A1 |
20060136022 | Wong et al. | Jun 2006 | A1 |
20060139569 | Schwebel | Jun 2006 | A1 |
20060154901 | Pflugfelder et al. | Jul 2006 | A1 |
20060157064 | Davison et al. | Jul 2006 | A1 |
20060183698 | Abelson | Aug 2006 | A1 |
20060223032 | Fried et al. | Oct 2006 | A1 |
20060233859 | Whitcup et al. | Oct 2006 | A1 |
20070016254 | Grenon et al. | Jan 2007 | A1 |
20070016256 | Korb et al. | Jan 2007 | A1 |
20070027411 | Ella et al. | Feb 2007 | A1 |
20070049913 | Grenon et al. | Mar 2007 | A1 |
20070088415 | Peyman | Apr 2007 | A1 |
20070173799 | Hsia | Jul 2007 | A1 |
20070191821 | Boxer Wachter | Aug 2007 | A1 |
20070203462 | Soroudi | Aug 2007 | A1 |
20070270760 | Dacquay et al. | Nov 2007 | A1 |
20070280924 | Daniels et al. | Dec 2007 | A1 |
20070282282 | Wong et al. | Dec 2007 | A1 |
20080051741 | Grenon et al. | Feb 2008 | A1 |
20080075787 | Hibino | Mar 2008 | A1 |
20080081999 | Gravely et al. | Apr 2008 | A1 |
20080082057 | Korb et al. | Apr 2008 | A1 |
20080109053 | Grenon et al. | May 2008 | A1 |
20080114423 | Grenon et al. | May 2008 | A1 |
20080114425 | Korb et al. | May 2008 | A1 |
20080114427 | Korb et al. | May 2008 | A1 |
20080132973 | Lord et al. | Jun 2008 | A1 |
20080132978 | Korb et al. | Jun 2008 | A1 |
20080275533 | Powell | Nov 2008 | A1 |
20090043365 | Friedland et al. | Feb 2009 | A1 |
20090137533 | Adkins, Jr. | May 2009 | A1 |
20090306111 | Nakamura et al. | Dec 2009 | A1 |
20100100029 | Maskin | Apr 2010 | A1 |
20100121420 | Fiset et al. | May 2010 | A1 |
20100152645 | Ogasawara | Jun 2010 | A1 |
20100152719 | Fujikawa | Jun 2010 | A1 |
20100292630 | Maskin | Nov 2010 | A1 |
20110022010 | Grenon et al. | Jan 2011 | A1 |
20110039805 | Pflugfelder et al. | Feb 2011 | A1 |
20110059902 | Sullivan et al. | Mar 2011 | A1 |
20110059925 | Donnenfeld | Mar 2011 | A1 |
20110130729 | Korb et al. | Jun 2011 | A1 |
20110196353 | DeLand | Aug 2011 | A1 |
20110251532 | Yang | Oct 2011 | A1 |
20110273550 | Amano et al. | Nov 2011 | A1 |
20110319794 | Gertner | Dec 2011 | A1 |
20120016450 | Korb et al. | Jan 2012 | A1 |
20120065556 | Smith et al. | Mar 2012 | A1 |
20120088980 | Gravely et al. | Apr 2012 | A1 |
20120109041 | Munz | May 2012 | A1 |
20120136285 | Korb et al. | May 2012 | A1 |
20120209154 | Williams, III et al. | Aug 2012 | A1 |
20120215073 | Sherman et al. | Aug 2012 | A1 |
20120221081 | Hof et al. | Aug 2012 | A1 |
20130053733 | Korb et al. | Feb 2013 | A1 |
20130110101 | Van Valen et al. | May 2013 | A1 |
20130172829 | Badawi | Jul 2013 | A1 |
20130172959 | Azoulay | Jul 2013 | A1 |
20140330129 | Grenon et al. | Nov 2014 | A1 |
20150005750 | Kelleher | Jan 2015 | A1 |
20150025545 | Grenon et al. | Jan 2015 | A1 |
20150057701 | Kelleher | Feb 2015 | A1 |
20150100063 | Korb et al. | Apr 2015 | A1 |
20160106576 | Badawi et al. | Apr 2016 | A1 |
20180092773 | Kelleher et al. | Apr 2018 | A1 |
20190091065 | Kelleher et al. | Mar 2019 | A1 |
Number | Date | Country |
---|---|---|
2679448 | Sep 2008 | CA |
2400107 | Oct 2000 | CN |
19645432 | May 1998 | DE |
202005011496 | Jul 2006 | DE |
1587468 | Jan 2011 | EP |
2151438 | Oct 2012 | EP |
H7-28523 | May 1995 | JP |
H1085248 | Apr 1998 | JP |
2004236727 | Aug 2004 | JP |
2006198249 | Aug 2006 | JP |
2008-540051 | Nov 2008 | JP |
2010-516343 | May 2010 | JP |
2010155012 | Jul 2010 | JP |
WO-9909920 | Mar 1999 | WO |
WO-9909965 | Mar 1999 | WO |
WO-9920213 | Apr 1999 | WO |
WO-9958131 | Nov 1999 | WO |
WO-0205743 | Jan 2002 | WO |
WO-02056781 | Jul 2002 | WO |
WO-03061535 | Jul 2003 | WO |
WO-03072008 | Sep 2003 | WO |
WO-2004041134 | May 2004 | WO |
WO-2006058189 | Jun 2006 | WO |
WO-2006093851 | Sep 2006 | WO |
WO-2006125106 | Nov 2006 | WO |
WO-2008024100 | Feb 2008 | WO |
WO-2008072169 | Jun 2008 | WO |
WO-2008089327 | Jul 2008 | WO |
WO-2008106228 | Sep 2008 | WO |
WO-2009064834 | May 2009 | WO |
WO-2010005527 | Jan 2010 | WO |
WO-2010056848 | May 2010 | WO |
WO-2011067941 | Jun 2011 | WO |
Entry |
---|
Kent, Christopher. “Intense Pulsed Light: for Treating Dry Eye.” Review of Ophthalmology. Nov. 16, 2010. 4 pages. |
Outram, Bernie. “Black Coatings to Reduce Stray Light.” OPTI 521—Optomechanical Engineering. Fall 2009. 13 pages. |
Ayliffe, William. “Blepharitis and Meibomian Gland Dysfunction.” Smolin and Thoft's The Cornea: Scientific Foundations & Clinical Practice. Ed. C. S. Foster. 4th ed. 2005. 649-50. |
Bickerton, Reginald E. “Notes on Ophthalmology in Vienna.” The British Medical Journal (1898): 818-21. |
Connor, Leartus, Hot Water in the Management of Eye Diseases. Some Suggestions. Detroit: D.O. Haynes, (1887). 18 pages. |
Fein, W. “Cautery Applications to Relieve Punctal Stenosis.” Archives of Ophthalmology 95.1 (1977): 145-46. |
Friedland, Beth R., Christopher P. Fleming, Caroline A. Blackie, and Donald R. Korb. “A Novel Thermodynamic Treatment for Meibomian Gland Dysfunction.” Current Eye Research 36.2 (2011): 79-87. Print. |
Goto, E. “Treatment of Non-inflamed Obstructive Meibomian Gland Dysfunction by an Infrared Warm Compression Device.” British Journal of Ophthalmology 86.12 (2002): 1403-407. |
Gutgesell, Vicki J., George A. Stern, and C. Ian Hood. “Histopathology of Meibomian Gland Dysfunction.” American Journal of Ophthalmology 94.3 (1982): 383-87. |
Henriquez, A. S., and D. R. Korb. “Meibomian Glands and Contact Lens Wear.” British Journal of Ophthalmology 65.2 (1981): 108-11. |
Jester, J. V. et al. “Meibomian Gland Dysfunction.” Investigative Ophthalmology & Visual Science 30 (1989): 927-51. |
Korb, D. R., and A. S. Henriquez. “Meibomian Gland Dysfunction and Contact Lens Intolerance.” J. Amer Optometric Assoc. 51.3 (1980): 243-51. |
Korb, Donald R., and Jack V. Greiner. “Increase in Tear Film Lipid Layer Thickness Following Treatment of Meibomian Gland Dysfunction.” Advances in Experimental Medicine and Biology Lacrimal Gland, Tear Film, and Dry Eye Syndromes (1994): 293-98. |
Minco. Flexible Heaters Design Guide. (2007). 64 pages. |
Mori, A. “Disposable Eyelid-warming Device for the Treatment of Meibomian Gland Dysfunction.” Japanese Journal of Ophthalmology 47.6 (2003): 578-86. |
Mori, Asako, Yoshihisa Oguchi, Eiki Goto, Katsu Nakamori, Tomohiro Ohtsuki, Fuminobu Egami, Jun Shimazaki, and Kazuo Tsubota. “Efficacy and Safety of Infrared Warming of the Eyelids.” Cornea 18.2 (1999): 188. |
Wise, Ryan J., Rachel K. Sobel, and Richard C. Allen. “Meibography: A Review of Techniques and Technologies.” Saudi Journal of Ophthalmology 26.4 (2012): 349-56. |
Yokoi, Norihiko. “Assessment of Meibomian Gland Function in Dry Eye Using Meibometry.” Archives of Ophthalmology Arch Ophthalmol 117.6 (1999): 723-29. |
Number | Date | Country | |
---|---|---|---|
20180001108 A1 | Jan 2018 | US |